首页> 外文期刊>Journal of clinical laboratory analysis. >Change of miRNA expression profiles in patients with knee osteoarthritis before and after celecoxib treatment
【24h】

Change of miRNA expression profiles in patients with knee osteoarthritis before and after celecoxib treatment

机译:塞来昔布治疗前后膝骨关节炎患者miRNA表达谱的变化

获取原文
           

摘要

Background This study aimed to investigate the change of circulating miRNA expression profiles in knee osteoarthritis (OA) patients before and after celecoxib treatment. Methods Two hundred and eighteen knee OA patients underwent celecoxib treatment for 6?weeks were enrolled. Plasma samples were obtained at baseline (W0) and at W6, and treatment efficacy were assessed by WOMAC index. In the exploration stage, miRNA expression profiles in plasma before and after treatment from 6 patients were detected by microarray. Subsequently, in the validation stage, 10 top differentially expressed miRNAs (DEMs) after and before treatment in microarray were further validated in all 218 patients by qPCR. Results In the exploration stage, patients after treatment could be distinguished from them before treatment by miRNAs expression profiles by PCA plot and heatmap analysis, and 45 up‐regulated and 48 down‐regulated miRNAs were identified by volcano plot. In the validation stage, miR‐126‐5p and miR‐320a levels increased at W6 compared to W0, while miR‐155‐5p and miR‐146a‐5p levels decreased. WOMAC pain/stiffness/physical function scores were all decreased at W6 compared to W0, and 71% of patients achieved clinical response. The increase of miR‐126‐5p expression (W6‐W0) in clinical responders was much larger compared to nonclinical responders. And miRNA‐320a level declined in nonclinical responders while increased in clinical responders. Conversely, miRNA‐146a‐5p level increased in nonclinical responders while decreased in clinical responders. Conclusion Circulating miRNA expression profiles act as important roles in knee OA patients underwent celecoxib treatment, and miR‐126‐5p, miR‐320a as well as miR‐146a‐5p might correlate with treatment response to celecoxib.
机译:背景本研究旨在研究塞来昔布治疗前后膝骨性关节炎(OA)患者循环miRNA表达谱的变化。方法218例接受celecoxib治疗6周的OA患者。在基线(W0)和W6获得血浆样品,并通过WOMAC指数评估治疗效果。在探索阶段,通过微阵列检测了6位患者治疗前后血浆中的miRNA表达谱。随后,在验证阶段,通过qPCR在所有218例患者中进一步验证了微阵列治疗前后的10种顶部差异表达的miRNA(DEM)。结果在探索阶段,可以通过PCA图和热图分析通过miRNA表达谱将治疗后的患者与治疗前的患者区分开,并通过火山图鉴定出45个上调和48个下调的miRNA。在验证阶段,与W0相比,第6周的miR‐126-5p和miR‐320a水平升高,而miR‐155‐5p和miR‐146a-5p水平降低。与第0周相比,第6周WOMAC的疼痛/僵硬/身体机能评分均降低,并且71%的患者达到了临床反应。与非临床应答者相比,临床应答者中miR-1256-5p表达(W6-W0)的增加要大得多。非临床反应者的miRNA-320a水平下降,而临床反应者的水平升高。相反,在非临床反应者中,miRNA-146a-5p水平升高,而在临床反应者中则降低。结论循环miRNA表达谱在接受塞来昔布治疗的膝骨OA患者中起重要作用,miR-126-5p,miR-320a和miR-146a-5p可能与对塞来昔布的治疗反应相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号